MEI Pharma(US:MEIP)2026-02-17 13:45Share Repurchase and Financing Activities - Lite Strategy, Inc. announced a share repurchase program authorized by the Board of Directors, allowing for the repurchase of up to $25.0 million in common stock [153]. - As of December 31, 2025, the company repurchased 137,541 shares at a weighted-average price of $1.47 per share [154]. - The company closed a $100.0 million Private Investment in Public Equity (PIPE) on July 22, 2025, issuing 23,216,898 shares at an offering price of $3.42 per share [160]. - In the three months ended December 31, 2025, the company realized gains of $0.5 million from Covered Call Options, using $0.2 million to repurchase 137,541 shares of Common Stock at an average cost of $1.47 per share [205]. - Net cash provided by financing activities for the six months ended December 31, 2025, was $96.6 million, associated with the issuance and sale of 23,216,898 shares of Common Stock and Pre-Funded Warrants [208]. - The company has no financing activities during the six months ended December 31, 2024, indicating a significant change in financing strategy [208]. Research and Development - The drug candidate pipeline includes voruciclib, an oral CDK9 inhibitor, and zandelisib, an oral PI3Kδ inhibitor, with pre-clinical development activities in nononcology disease indications commencing in Q2 FY 2026 [170][171]. - Voruciclib was previously studied in a Phase 1 trial for acute myeloid leukemia (AML) and B-cell malignancies, but all clinical trial activities were ceased in September 2024 [171]. - Research and development expenses decreased by approximately $3.4 million (98.4%) to $56,000 for the six months ended December 31, 2025, compared to $3.471 million for the same period in 2024 [197]. - Research and development expenses for voruciclib were $26,000 for the six months ended December 31, 2025, compared to $798,000 for the same period in 2024 [199]. - The company discontinued the clinical development of voruciclib in oncology as part of its strategic alternatives evaluation announced in July 2024 [204]. - Pre-clinical investigational activities in non-oncology disease indications for voruciclib commenced in the second quarter of fiscal year 2026 [204]. - The company’s future capital requirements will depend on various factors, including the costs and outcomes of regulatory reviews and clinical trials for product candidates [210]. Financial Performance and Position - General and administrative expenses decreased by $1.9 million (23.2%) to $6.4 million for the six months ended December 31, 2025, compared to $8.3 million for the same period in 2024 [200]. - Change in fair value of digital assets increased by $27.1 million (100.0%) to $27.1 million for the six months ended December 31, 2025, with no such investments in the comparable prior year period [197]. - Other (expense) income, net, decreased by approximately $2.0 million to a loss of $0.8 million for the six months ended December 31, 2025, compared to income of $1.1 million for the same period in 2024 [203]. - As of December 31, 2025, the company had $8.8 million in cash and cash equivalents and $64.0 million in unrestricted digital assets [204]. - The company has accumulated losses of $438.6 million since inception and expects to incur operating losses and generate negative cash flows from operations for the foreseeable future [204]. - For the six months ended December 31, 2025, net cash used in operating activities was $6.4 million, consisting of a net loss of $34.4 million and $1.8 million in changes in operating assets and liabilities, partially offset by $29.8 million for noncash items [206]. - Net cash used in investing activities for the six months ended December 31, 2025, was $99.4 million, primarily due to the acquisition of digital assets under the Litecoin Treasury Strategy [207]. Digital Asset Strategy - The company has initiated a Litecoin Treasury Strategy, acquiring LTC tokens to diversify reserves and enhance capital efficiency [155][163]. - The fair value of the company's digital assets, primarily LTC tokens, is subject to market fluctuations, which could materially affect investments [164]. - The company has entered into contracts with GSR Markets Ltd to write covered call options on certain LTC holdings as part of its digital asset treasury management strategy [156]. - The company aims to align with emerging financial technologies and may consider LTC mining or other crypto-focused operational activities in the future [163]. - The valuation of covered call options is marked-to-market at each reporting period, with changes recognized in the condensed consolidated statements of operations [214]. - A 10% increase in historical volatility utilized to estimate the grant date fair value of the Advisory Warrants would have resulted in an increase of $0.7 million in the grant date fair value [212]. - A 10% increase in the forward price as of December 31, 2025, would have resulted in an increase of $0.1 million in the fair value of derivative liabilities related to covered call options [216]. - The company has potential purchase obligations that could materially affect its financial position, results of operations, and cash flows, depending on future events [209].